Lv78
5000 积分 2022-10-25 加入
Application of fucosylation inhibitors for production of afucosylated antibody
1天前
已完结
Evolving roles of MET as a therapeutic target in NSCLC and beyond
8天前
已完结
Strategies to reduce the use of non-human primates in the development of oncology therapeutics: CD3-bispecifics
8天前
已完结
A transposon-based transient transfection system in CHO-K1 cells enables quality prediction of stable cell line proteins
22天前
已完结
Optimization of a novel 2+2 BCMA x CD3 bispecific antibody for minimized cytokine release and potent efficacy
29天前
已完结
One-year remission of therapy-resistant SLE after a single course with the bispecific CD3: BCMA antibody teclistamab, but induction of a non-infectious Crohn’s-like inflammatory bowel disease
29天前
已完结
Artificial intelligence in therapeutic antibody design: Advances and future prospects
1个月前
已完结
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis
1个月前
已完结
Accelerating IND‐enabling toxicology studies using protein products from stable pools or pools of clones in Chinese hamster ovary cells
2个月前
已完结
SOHO State of the Art Updates and Next Questions | Manuscript Title: Bispecific T-Cell Engagers: Sequencing, B-Cell Maturation Antigen, GPRC5D, and Resistance
2个月前
已关闭
皖公网安备34019202002308
